Athari BioSciences
Athari BioSciences is dedicated to transforming healthcare through innovative research, diagnostics, and training. Guided by a mission to improve public health, foster STEMM workforce development, and make healthcare accessible, the company operates a CLIA-certified BSL-2 laboratory and engages in cutting-edge therapeutics, vaccine development, and genomic research. With a focus on impact, Athari BioSciences collaborates across sectors to create solutions that matter, emphasizing excellence, equity, and community empowerment.
Industries
Nr. of Employees
small (1-50)
Athari BioSciences
45925 Horseshoe Drive, Suite 170, Sterling, VA 20166
Products
Dual-reporter neutralization and cytotoxicity assay (pseudovirus/VLP)
A high-throughput assay that quantifies neutralizing antibodies and measures cytotoxicity in parallel using a non-replicating pseudovirus or virus-like particle system with luminescent and fluorescent reporters; designed for rapid variant adaptation and decentralized sample compatibility.
Nanoparticle delivery and oral vaccine formulation platform
Nanoparticle-based delivery systems engineered for targeted delivery of gene-modulating therapies and chemotherapeutic payloads, and formulations optimized for oral vaccine delivery with strategies for gastric stability and mucosal targeting.
Dual-reporter neutralization and cytotoxicity assay (pseudovirus/VLP)
A high-throughput assay that quantifies neutralizing antibodies and measures cytotoxicity in parallel using a non-replicating pseudovirus or virus-like particle system with luminescent and fluorescent reporters; designed for rapid variant adaptation and decentralized sample compatibility.
Nanoparticle delivery and oral vaccine formulation platform
Nanoparticle-based delivery systems engineered for targeted delivery of gene-modulating therapies and chemotherapeutic payloads, and formulations optimized for oral vaccine delivery with strategies for gastric stability and mucosal targeting.
Services
Support for early-stage R&D including molecular cloning, viral vector and nanoparticle design, in vitro assay development and preclinical testing to advance therapeutics, vaccines and diagnostic platforms.
Provision of diagnostic and high-complexity laboratory testing, assay validation, and CLIA-compliant workflows including molecular and immunoassay services for clinical and surveillance needs.
Hands-on STEMM education, internships, mentorship programs and workforce training delivered in a CLIA BSL-2 laboratory to prepare students and early-career professionals for roles in life sciences and genomic research.
High-throughput neutralization and immunosurveillance testing using modular pseudovirus/VLP and dual-reporter assays designed for rapid variant adaptation and field-compatible sample collection.
Business development, proposal capture, program management and consulting to support government and commercial partnerships, including grants, SBIRs and contract transitions to program-of-record.
Partnerships and outreach programs focused on genomic education, mentoring and diversity in STEMM to increase inclusion in research and build local talent pipelines.
Support for early-stage R&D including molecular cloning, viral vector and nanoparticle design, in vitro assay development and preclinical testing to advance therapeutics, vaccines and diagnostic platforms.
Provision of diagnostic and high-complexity laboratory testing, assay validation, and CLIA-compliant workflows including molecular and immunoassay services for clinical and surveillance needs.
Hands-on STEMM education, internships, mentorship programs and workforce training delivered in a CLIA BSL-2 laboratory to prepare students and early-career professionals for roles in life sciences and genomic research.
High-throughput neutralization and immunosurveillance testing using modular pseudovirus/VLP and dual-reporter assays designed for rapid variant adaptation and field-compatible sample collection.
Business development, proposal capture, program management and consulting to support government and commercial partnerships, including grants, SBIRs and contract transitions to program-of-record.
Partnerships and outreach programs focused on genomic education, mentoring and diversity in STEMM to increase inclusion in research and build local talent pipelines.
Expertise Areas
- Clinical laboratory diagnostics and LDT validation
- Neutralizing antibody testing and immunosurveillance
- Viral vector and pseudovirus/VLP platform development
- Nanoparticle therapeutics and oral vaccine formulation
Key Technologies
- Pseudovirus / virus-like particle (VLP) platforms
- Dual-reporter luminescent and fluorescent assays
- RT-qPCR molecular diagnostics
- Multicolor flow cytometry
News & Updates
A reflection on milestones, growth, and impact in 2024, including advancements in cancer therapeutics, immunization platforms, and workforce training.
Athari BioSciences at WVC 2025: Engineering Precision Platforms for a New Era of Vaccine Development
Showcasing next-generation neutralizing antibody assays and innovative platforms for rapid viral immunity assessment at the World Vaccine Congress 2025.
A comprehensive review of the year's milestones, including breakthroughs in cancer therapeutics, vaccine technology, and genomic research.
Reflecting on Dr. Martin Luther King Jr.'s insights on the balance of scientific progress and moral development, and Athari BioSciences' commitment to community and equity.
A reflection on milestones, growth, and impact in 2024, including advancements in cancer therapeutics, immunization platforms, and workforce training.
Athari BioSciences at WVC 2025: Engineering Precision Platforms for a New Era of Vaccine Development
Showcasing next-generation neutralizing antibody assays and innovative platforms for rapid viral immunity assessment at the World Vaccine Congress 2025.
A comprehensive review of the year's milestones, including breakthroughs in cancer therapeutics, vaccine technology, and genomic research.
Reflecting on Dr. Martin Luther King Jr.'s insights on the balance of scientific progress and moral development, and Athari BioSciences' commitment to community and equity.